Roquefort Therapeutics (LON:ROQ) Shares Up 4.3% – Still a Buy?

Roquefort Therapeutics plc (LON:ROQ) shot up 4.3% on Friday . The company traded as high as GBX 1.80 ($0.02) and last traded at GBX 1.77 ($0.02). 3,842,397 shares were traded during trading, an increase of 116% from the average session volume of 1,782,012 shares. The stock had previously closed at GBX 1.70 ($0.02).

Roquefort Therapeutics Trading Up 10.9 %

The company has a market capitalization of £2.40 million, a PE ratio of -1.56 and a beta of 0.05. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The stock has a fifty day moving average of GBX 3.27 and a two-hundred day moving average of GBX 3.74.

Insider Activity at Roquefort Therapeutics

In related news, insider Stephen Paul West purchased 400,000 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were acquired at an average cost of GBX 3 ($0.04) per share, with a total value of £12,000 ($15,092.44). 60.40% of the stock is currently owned by insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.